PURPOSE: To compare the outcomes of two neoadjuvant radiochemotherapy (N-RCT) regimens for squamous cell carcinoma of the esophagus (ESCC). METHODS: The standard N-RCT regimen for ESCC at our institution between 2002 and 2011 was a total dose of 45 Gy (1.8-Gy fractions) with concomitant cisplatin (20 mg/m(2), days 1-5 and 29-33) and 5-fluorouracil (5-FU; 225 mg/m(2), 24 h continuous infusion on days 1-33). During the same period, a phase I/II study comparing the standard ESCC N-RCT protocol with a regimen identical except for the replacement of cisplatin with weekly oxaliplatin (40-50 mg/m(2)) was performed at our center. The standard regimen was used to treat 40 patients; 37 received the oxaliplatin regimen. All patients subsequently underwent radical resection with reconstruction according to tumor location and two-field lymph node dissection. RESULTS: Median follow-up time from the start of N-RCT was 74 months (range 3-116 months). The two patient groups were comparable in terms of demographic and baseline tumor characteristics. R0 resection was achieved in 37/39 patients (95 %) in the cisplatin-based N-RCT group, compared to 24/37 (65 %) in the oxaliplatin-based group (p = 0.002). A pathological complete response (pCR) was seen in the resection specimens from 18/39 patients (46 %) in the cisplatin-based N-RCT group and in 8/37 (22 %) oxaliplatin-group patients. In the cisplatin group, 2- and 5-year overall survival (OS) rates were 67 ± 8 % and 60 ± 8 %, respectively (median OS 103 months), compared to 38 ± 8 % and 32 ± 8 %, respectively, for the oxaliplatin group (median OS 17 months; hazard ratio, HR 0.452; 95 % confidence interval, CI 0.244-0.839; p = 0.012). CONCLUSION:Oxaliplatin-based N-RCT resulted in poorer outcomes in ESCC patients and should not routinely replace cisplatin-based N-RCT.
RCT Entities:
PURPOSE: To compare the outcomes of two neoadjuvant radiochemotherapy (N-RCT) regimens for squamous cell carcinoma of the esophagus (ESCC). METHODS: The standard N-RCT regimen for ESCC at our institution between 2002 and 2011 was a total dose of 45 Gy (1.8-Gy fractions) with concomitant cisplatin (20 mg/m(2), days 1-5 and 29-33) and 5-fluorouracil (5-FU; 225 mg/m(2), 24 h continuous infusion on days 1-33). During the same period, a phase I/II study comparing the standard ESCC N-RCT protocol with a regimen identical except for the replacement of cisplatin with weekly oxaliplatin (40-50 mg/m(2)) was performed at our center. The standard regimen was used to treat 40 patients; 37 received the oxaliplatin regimen. All patients subsequently underwent radical resection with reconstruction according to tumor location and two-field lymph node dissection. RESULTS: Median follow-up time from the start of N-RCT was 74 months (range 3-116 months). The two patient groups were comparable in terms of demographic and baseline tumor characteristics. R0 resection was achieved in 37/39 patients (95 %) in the cisplatin-based N-RCT group, compared to 24/37 (65 %) in the oxaliplatin-based group (p = 0.002). A pathological complete response (pCR) was seen in the resection specimens from 18/39 patients (46 %) in the cisplatin-based N-RCT group and in 8/37 (22 %) oxaliplatin-group patients. In the cisplatin group, 2- and 5-year overall survival (OS) rates were 67 ± 8 % and 60 ± 8 %, respectively (median OS 103 months), compared to 38 ± 8 % and 32 ± 8 %, respectively, for the oxaliplatin group (median OS 17 months; hazard ratio, HR 0.452; 95 % confidence interval, CI 0.244-0.839; p = 0.012). CONCLUSION:Oxaliplatin-based N-RCT resulted in poorer outcomes in ESCC patients and should not routinely replace cisplatin-based N-RCT.
Authors: P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245
Authors: J Boda-Heggemann; C Weiss; V Schneider; R-D Hofheinz; S Haneder; H Michaely; H Wertz; U Ronellenfitsch; A Hochhaus; F Wenz; F Lohr Journal: Strahlenther Onkol Date: 2013-04-06 Impact factor: 3.621
Authors: S Lorenzen; B Brücher; F Zimmermann; H Geinitz; J Riera; T Schuster; N Roethling; H Höfler; K Ott; C Peschel; J R Siewert; M Molls; F Lordick Journal: Br J Cancer Date: 2008-09-16 Impact factor: 7.640
Authors: Ti Zhang; Shuang Cai; Chad Groer; Wai Chee Forrest; Qiuhong Yang; Eva Mohr; Justin Douglas; Daniel Aires; Sandra M Axiak-Bechtel; Kimberly A Selting; Jeffrey A Swarz; Deborah J Tate; Jeffrey N Bryan; M Laird Forrest Journal: J Pharm Sci Date: 2016-05-04 Impact factor: 3.534
Authors: Arif Deniz Ordu; Carsten Nieder; Hans Geinitz; Philipp Günther Kup; Lisa Felicia Deymann; Vera Scherer; Stephanie E Combs; Khashayar Fakhrian Journal: Strahlenther Onkol Date: 2014-11-18 Impact factor: 3.621
Authors: Nina-Sophie Hegemann; Rebecca Koepple; Franziska Walter; David Boeckle; Wolfgang P Fendler; Martin Kurt Angele; Stefan Boeck; Claus Belka; Falk Roeder Journal: Strahlenther Onkol Date: 2018-01-18 Impact factor: 3.621
Authors: Philipp Günther Kup; Carsten Nieder; Hans Geinitz; Christoph Henkenberens; Angela Besserer; Markus Oechsner; Sabine Schill; Ralph Mücke; Vera Scherer; Stephanie E Combs; Irenäus A Adamietz; Khashayar Fakhrian Journal: J Cancer Date: 2015-01-20 Impact factor: 4.207